Clinical Trials Browser

Phase 1 × NIH × Brentuximab Vedotin × Clear all

NCT01902160 2015-11-09

Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

Hodgkin Disease